As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that GENEZIS has been accepted and welcomed as a new IGBA Associate Member.
IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM), is taking over the position of IGBA Chair for 2022 from Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA).
- IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access (November 2021)
- Global Biosimilars Week: Message of Sudarshan Jain, Chair, IGBA (October 2021)
- Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid (October 2021)
- Annual Conference Opening Remarks Suzette Kox (October 2021)